S&P 500
5.018,39 -17,30 (-0,34%) Nasdaq
15.605,48 -52,34 (-0,33%) NIKKEI 225
38.274,05 -131,61 (-0,34%) Dólar/Euro
1,0720 +0,0048 (+0,45%) Petróleo Brent
83,51 +0,07 (+0,08%) Bitcoin EUR
54.008,36 -2.285,37 (-4,06%)
Novartis AG (0QLR.IL)
Novartis AG
Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com
Sector(es): Healthcare
Sector: Drug Manufacturers - General
Empleados a tiempo completo: 103.000
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Vasant Narasimhan | Chief Exec. Officer | 5,14M | N/A | 1976 |
| Mr. Harry Kirsch | Chief Financial Officer | 2,61M | N/A | 1965 |
| Dr. Steffen Lang Ph.D. | Pres of Operations | 2,14M | N/A | 1967 |
| Dr. Klaus Moosmayer Ph.D. | Chief Ethics, Risk & Compliance Officer | 1,42M | N/A | 1968 |
| Ms. Karen L. Hale | Chief Legal Officer | 2,14M | N/A | 1968 |
| Dr. Robert Kowalski Pharm.D. | Chief People & Organization Officer | 1,92M | N/A | 1968 |
| Mr. Victor Bulto | Pres of US | 2,39M | N/A | N/A |
| Dr. Shreeram Aradhye M.D. | Pres of Global Drug Devel. & Chief Medical Officer | 2,09M | N/A | 1963 |
| Mr. Aharon Gal Ph.D. | Chief Strategy & Growth Officer | 5,75M | N/A | N/A |
| Dr. Fiona H. Marshall Ph.D. | Pres of BioMedical Research | 5,3M | N/A | 1964 |
Descripción
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Gobierno corporativo
El ISS Governance QualityScore de Novartis AG, a día 1 de octubre de 2023, es 1. Las puntuaciones base son Auditoría: 1; Tablero: 2; Derechos de los accionistas: 1; Compensación: 1.
